Barker E N, Campbell S, Tebb A J, Neiger R, Herrtage M E, Reid S W J, Ramsey I K
Department of Veterinary Clinical Studies, University of Glasgow, Bearsden Road, Bearsden, Glasgow G61 1QH, Scotland.
J Vet Intern Med. 2005 Nov-Dec;19(6):810-5. doi: 10.1892/0891-6640(2005)19[810:acotst]2.0.co;2.
The survival times of 148 dogs treated for pituitary-dependent hyperadrenocorticism were studied using clinical records from 3 UK veterinary centers between 1998 and 2003. Of these animals, 123 (83.1%) were treated with trilostane, while 25 (16.9%) were treated with mitotane. Treatment groups were compared using t-tests and analysis of variance (or their nonparametric equivalents) and chi-square tests. Survival data were analyzed using Kaplan-Meier survival plots and Cox proportional hazard methods. There was no significant difference between the population attributes from each center or between treatment groups. The median survival time for animals treated with trilostane was 662 days (range 8-1,971) and for mitotane it was 708 days (range 33-1,399). There were no significant differences between the survival times for animals treated with trilostane and those treated with mitotane. In the multivariable model (including drug, center, breed group, weight, diagnostic group, and age at diagnosis), only age at diagnosis and weight were significantly negatively associated with survival. Importantly, there was no significant effect of drug choice on survival.
利用1998年至2003年间英国3家兽医中心的临床记录，对148只接受垂体依赖性肾上腺皮质功能亢进治疗的犬的存活时间进行了研究。在这些动物中，123只（83.1%）接受曲洛司坦治疗，25只（16.9%）接受米托坦治疗。使用t检验、方差分析（或其非参数等效方法）和卡方检验对治疗组进行比较。使用Kaplan-Meier生存曲线和Cox比例风险方法分析生存数据。各中心的总体属性之间或治疗组之间没有显著差异。接受曲洛司坦治疗的动物的中位生存时间为662天（范围8 - 1971天），接受米托坦治疗的动物的中位生存时间为708天（范围33 - 1399天）。接受曲洛司坦治疗的动物和接受米托坦治疗的动物的生存时间之间没有显著差异。在多变量模型（包括药物、中心、品种组、体重、诊断组和诊断时的年龄）中，只有诊断时的年龄和体重与生存显著负相关。重要的是，药物选择对生存没有显著影响。
